
CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
FDA has approved a new formulation for zolpidem, a nonbenzodiazepine hypnotic, for short-term treatment of insomnia.





